ROCKVILLE, Md.--(BUSINESS WIRE)--Dec. 10, 2007--Emergent
BioSolutions Inc. (NYSE:EBS), announced today that company management
will be presenting at the following two investor conferences over the
next thirty day period.
-- The New York Society of Securities Analysts (NYSSA) Annual Biotech
& Specialty Pharma Conference
New York, NY.
December 12, 2007
Presentation Time: 10:55 am Eastern
-- J.P. Morgan 26th Annual Healthcare Conference
St. Francis Hotel
San Francisco, CA.
January 9, 2007
Presentation Time: 10:30 am Pacific
During these presentations, senior management will provide a
corporate overview, including a discussion of product development
programs, recent corporate activities and financial performance.
Webcasts of each of these presentations will be available both
live and by replay. To access either the live or archived webcast for
either presentation, please proceed to www.emergentbiosolutions.com,
click on the "Investors" link and proceed to the "Webcasts &
Presentations" section, beginning on the day of the specific
An archived replay of each webcast will be available 24 hours
after the live presentation.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company
dedicated to one simple mission--to protect life. We develop,
manufacture and commercialize immunobiotics, consisting of vaccines
and therapeutics that assist the body's immune system to prevent or
treat disease. Our biodefense business focuses on immunobiotics for
use against biological agents that are potential weapons of
bioterrorism and biowarfare. Our marketed product, BioThrax(R)
(Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S.
Food and Drug Administration for the prevention of anthrax disease.
Our commercial business focuses on immunobiotics for use against
infectious diseases and other medical conditions that have resulted in
significant unmet or underserved public health needs. More information
on the company is available at www.emergentbiosolutions.com.
CONTACT: Emergent BioSolutions Inc.
Robert G. Burrows
Vice President, Investor Relations
Director, Corporate Communications
SOURCE: Emergent BioSolutions Inc.